SCYNEXIS, Inc. Reports Third Quarter 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SCYNEXIS, Inc. Reports Third Quarter 2014 Financial Results

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq: SCYX ) today reported financial results for the third quarter ended September 30, 2014.

"This quarter we've taken two important steps forward in the development of SCY-078 for treatment of patients with invasive fungal infections," said Yves J. Ribeill, Ph.D., President and CEO of SCYNEXIS. "First, we are actively screening for patients and are on track to dose the first patient in our Phase 2 study of invasive Candida infections before year-end. Additionally, the recent licensing of SCY-635 to Waterstone Pharmaceutical allows us to continue to increase our focus on SCY-078 and the ongoing Phase 2 development activities of this important potential therapy."

Recent Developments

  • Initiated patient screening for enrollment in our Phase 2 clinical trial of SCY-078 for the treatment of invasive Candida infections.
  • Expect to enroll the first patient in our Phase 2 clinical trial for SCY-078 before the end of 2014.
  • Entered into an exclusive, worldwide license agreement granting Waterstone Pharmaceutical (HK Limited) rights for the development and commercialization of our proprietary compound, SCY-635, for the treatment of viral diseases in humans, as well as the option to license two additional cyclophilin inhibitors from SCYNEXIS.

2014 Third Quarter Financial Results

SCYNEXIS reported a net loss of $3.8 million, or $0.45 per diluted common share, for the third quarter of 2014, compared to a net loss of $4.0 million, or $11.79 per diluted common share, for the third quarter of 2013. [1]

Research and development expenses for the third quarter of 2014 increased to $2.5 million, compared to $1.1 million for the same period in 2013. The increase of $1.4 million was primarily due to increased costs associated with the SCY-078 Phase 2 clinical trial and the preclinical development of intravenous SCY-078.

Cash and cash equivalents totaled $34.0 million as of September 30, 2014.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com .

Forward Looking Statement

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

         
SCYNEXIS, INC.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
         
  Three months ended September 30, Nine months ended September 30,
  2014 2013 2014 2013
Revenue — related party $ 1,822 $ 1,822 $ 5,466 $ 5,466
Revenue 2,558 2,341 8,261 7,718
Total revenue 4,380 4,163 13,727 13,184
Cost of revenue 3,660 3,986 11,800 12,531
Gross profit 720 177 1,927 653
Operating expenses:        
Research and development 2,478 1,050 5,621 3,203
Selling, general and administrative 2,046 1,141 5,507 3,150
Gain on insurance recovery — — (165) —
Gain on sale of asset — (2) — (988)
Total operating expenses 4,524 2,189 10,963 5,365
Loss from operations (3,804) (2,012) (9,036) (4,712)
Other (income) expense:        
Amortization of deferred financing costs and debt discount — 982 755 2,504
Loss on extinguishment of debt — — 1,389 —
Interest expense — related party — 249 — 703
Interest expense — 46 49 142
Derivative fair value adjustment — 671 (10,080) 671
Other expense — — 10 —
Total other (income) expense: — 1,948 (7,877) 4,020
Net loss $ (3,804) $ (3,960) $ (1,159) $ (8,732)
Deemed dividend for beneficial conversion feature on Series D-2 preferred stock — — (909) —
Deemed dividend for antidilution adjustments to convertible preferred stock — — (214) —
Accretion of convertible preferred stock — — (510) —
Net loss attributable to common stockholders $ (3,804) $ (3,960) $ (2,792) $ (8,732)
Net loss per share attributable to common stockholders: [1]        
Basic $ (0.45) $ (11.79) $ (0.59) $ (25.99)
Diluted $ (0.45) $ (11.79) $ (2.59) $ (25.99)
Weighted average shares outstanding:        
Basic 8,504,785 335,938 4,703,278 335,930
Diluted 8,504,785 335,938 4,976,965 335,930
         
         
[1] The issuance of common stock and the conversion of convertible preferred stock to common stock in conjunction with our IPO in May 2014 caused a significant increase in common shares outstanding and impacted the comparability of our net loss per share calculations between 2013 and 2014 periods.
     
SCYNEXIS, INC.
UNAUDITED CONDENSED BALANCE SHEET DATA
(in thousands)
     
  September 30, 2014 December 31, 2013
Cash and cash equivalents $ 34,036 $ 1,402
Total current assets 36,798 2,953
Total assets 41,964 12,387
Total current liabilities 3,197 18,477
Total liabilities 5,822 33,339
Total convertible preferred stock — 87,157
Total stockholders' equity (deficit) 36,142 (108,109)
Total liabilities, convertible preferred stock, and stockholders' equity (deficit) 41,964 12,387

Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781-235-3060 E-mail: SCYNEXIS, Inc. Chuck Osborne Chief Financial Officer Tel: 919-544-8600 E-mail: Investor Relations Jillian Connell The Trout Group LLC Tel: 646-378-2956 E-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 85

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 69

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 62

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 60

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 99

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 58

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 89

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading

Top 5 Most Recently Viewed Articles

OFG Bancorp Reports Stellar Growth in 2024 Financial Results

Updated Category News Views 221

OFG Bancorp's Impressive Financial Results for 2024 OFG Bancorp (NYSE: OFG), the financial holding company for Oriental Bank, has reported robust financial performance for the fourth quarter and full year ended December 31, 2024. This remarkable growth marks an important milestone as the bank continues to enhance its services and strengthen its market positioning. Fourth...

Continue Reading
Innovative Dose Escalation Strategy for Infliximab Therapy

Updated Category News Views 404

Innovative Dose Escalation Strategy for Infliximab Therapy Celltrion, a prominent biopharmaceutical company based in Incheon, South Korea, recently unveiled exciting findings regarding the two-year efficacy of dose escalation therapy with subcutaneous infliximab, known as CT-P13 SC. These results were announced at the United European Gastroenterology (UEG) Week 2024. The...

Continue Reading
Understanding the Impact of Rising Repo Activity on Funding

Updated Category News Views 228

The Rising Repo Activity and Its Implications The recent rise in overnight repurchase agreements, commonly referred to as repos, has significantly influenced the financial landcape. This surge has put immense stress on banks that serve as intermediaries in these transactions, creating potential funding pressures at crucial periods such as quarter-ends and year-ends. What...

Continue Reading
Recent Lawsuit Over Securities at Perpetua Resources Corp. Highlights Shareholder Rights

Updated Category News Views 158

Understanding the Class Action Lawsuit Against Perpetua Resources Corp Levi & Korsinsky, LLP is raising awareness about a class action lawsuit impacting shareholders of Perpetua Resources Corp. This initiative is crucial for investors who experienced losses due to alleged securities fraud associated with the company's operations. Class Definition and Purpose The lawsuit...

Continue Reading
Exciting New Pickleball Kingdom Facility Set for Kentucky

Updated Category News Views 617

Exciting Announcement for Pickleball Enthusiasts Pickleball Kingdom, recognized as the world's largest indoor pickleball organization, is thrilled to announce its latest facility opening in Lexington, Kentucky. With a plan to cover an impressive 42,300 square feet, this state-of-the-art venue will feature 17 professional-grade indoor courts designed to deliver an ultimate...

Continue Reading